The global preeclampsia diagnostics market is witnessing steady expansion as healthcare systems place greater emphasis on early detection, risk assessment, and monitoring of pregnancy-related hypertensive disorders. Preeclampsia is a pregnancy-specific multisystem disorder generally associated with new-onset hypertension after 20 weeks of gestation, often accompanied by proteinuria or other signs of maternal organ dysfunction. The condition affects an estimated 2% to 8% of pregnancies worldwide and can lead to severe maternal and fetal complications when not identified and managed appropriately. Growing awareness among pregnant women and healthcare professionals, increasing availability of diagnostic technologies, and greater attention to maternal health are supporting demand for reliable diagnostic solutions. In parallel, companies are investing in research and development to introduce advanced testing technologies capable of improving diagnostic accuracy and supporting earlier identification of women at elevated risk.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=32423

Market Size and Growth

The global preeclampsia diagnostics market was valued at approximately US$ 1.5 Bn in 2021 and is projected to grow at a CAGR of 3.8% to reach US$ 2.3 Bn by the end of 2031. Market expansion is being supported by the increasing prevalence of preeclampsia and growing recognition of the importance of timely diagnosis during pregnancy. Risk factors such as advanced maternal age, obesity, diabetes, lifestyle changes, poor diet, physical inactivity, and stress are contributing to the broader burden of hypertensive disorders during pregnancy in several markets. Increased funding for research, diagnosis, and treatment is another important growth factor. Organizations and foundations are supporting research initiatives aimed at understanding preeclampsia and developing improved approaches to diagnosis and management, while healthcare providers are increasingly adopting diagnostic testing as part of comprehensive maternal monitoring programs.

Market Segmentation

By product and services, the market is segmented into instruments, reagents & consumables, and services. The services segment is expected to maintain a leading position as diagnostic laboratories and healthcare facilities incur recurring costs associated with sample collection, laboratory personnel, pathologist services, reporting, facility operations, and related diagnostic activities. By diagnostic type, blood tests represented the dominant segment, accounting for more than 55% of the market in 2021. Biochemical blood testing has gained attention because it can provide useful information for predicting or identifying preeclampsia during different stages of pregnancy, particularly in cases where early-onset disease is a concern. By end user, hospitals accounted for the largest share in 2021. Women with severe preeclampsia often require close monitoring, repeated blood and urine testing, and access to specialized maternal and emergency care, supporting the continued importance of hospitals within the diagnostic ecosystem.

Regional Analysis

North America represented the leading regional market, accounting for approximately 35% of global revenue in 2021. The regional market is projected to expand at a CAGR of more than 3.6% during the forecast period, supported by growing awareness of preeclampsia, established healthcare infrastructure, availability of diagnostic technologies, and continued research and development activities. Healthcare organizations and industry participants are increasingly focusing on improved approaches for detecting and monitoring the condition, creating opportunities for diagnostic technology providers. Asia Pacific, meanwhile, was identified as the fastest-growing regional market in 2021 and is projected to register a CAGR of approximately 4.4%. Increasing awareness, a large and growing pregnancy population, rising prevalence of preeclampsia, improving healthcare infrastructure, and greater availability of diagnostic tests in countries such as India and China are expected to support regional expansion.

Competitive Landscape

The global preeclampsia diagnostics market is relatively consolidated, with several established healthcare and diagnostics companies competing through product development, technological innovation, portfolio expansion, strategic collaborations, and mergers and acquisitions. Leading participants include Abbott Laboratories, ACON Laboratories, Inc., ARKRAY, Inc., Bio-Rad Laboratories, Inc., Cardinal Health, Danaher Corporation through Beckman Coulter, Inc., Diabetomics, Inc., DIRUI Industrial Co., Ltd., F. Hoffmann-La Roche Ltd., Metabolomic Diagnostics Ltd., Sera Prognostics, and Siemens Healthineers AG. Research and development remains a central competitive strategy as companies seek to develop more accurate, accessible, and efficient diagnostic solutions that can support clinicians in identifying women at risk of preeclampsia and monitoring disease progression.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453